Biotech Blog

18 November 2003

Is That Daylight for ImClone?

Is That Daylight for ImClone?
The beleaguered drugmaker finally gets some good news with Swiss approval of its cancer-fighting drug Erbitux

No Comments currently posted.

Post a comment on this entry:

Name required

Mail (will not be published) required

Website

•  
  
   
  

• Similar Posts

  • Puncturing The ImClone Hype
  • Enigmatic ImClone
  • Biotech sector keeps surging / Cancer drug news and FDA approvals create optimism
  • Is ImClone Out of the Woods?
  • ImClone Hammered as Sales Lag Estimates

• Recent Posts

  • Seeking reviewers and contributors for next edition of Building Biotechnology
  • Dyadic founder fights to regain control of company
  • Drug Patent Expirations in May 2008
  • Why so quiet?
  • Journal of Commercial Biotechnology — March 2008

• Recent Comments

  • mohammed Filali on Seeking reviewers and contributors for next edition of Building Biotechnology
  • smaranya.com » Blog Archive » Seeking reviewers and contributors for next edition of Building Biotechnology on Contact
  • Biotech Blog » Seeking reviewers and contributors for next edition of Building Biotechnology on Contact
  • smaranya.com » Journal of Commercial Biotechnology — March 2008 on Journal of Commercial Biotechnology — March 2008
  • Guido Cavakliere on Want biotechnology venture capital? Use a shotgun!

• Links

  • Biotechnology Career Development
  • Biotechnology Case Studies
  • Biotechnology Glossary
  • Introduction to Molecular Biology
  • Pharmaceutical Innovation Dashboard

• Other Biotech Blogs

  • BioHealth Investor
  • Colorado Life Science Deal Flow
  • Drug Wonks
  • FasterCures
  • GMO Africa Blog
  • In the Pipeline
  • Patent Baristas
  • Pharma Marketing Blog
  • Pharmalot
  • The Biotech Weblog

• Meta

  • Register
  • Log in
  • Entries RSS
  • Comments RSS
  • WordPress.org